← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #607 OF 1,000 MOST-CITED

Following manufacturer's instructions

FDA cited this observation 38 times across 36 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Biologics38
BY FISCAL YEAR
FY20266
FY20257
FY20242
FY20233
FY20223
FY20191
FY20186
FY20176
FY20164

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0× the rate of the average FDA-cited firm (0.0% vs 7.7%), across 36 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.

The American National Red Cross · Greenwich, Connecticut · Biologics · 2026-05-06

Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.

University of Vermont Health Network - Adirondack Blood Center · Plattsburgh, New York · Biologics · 2026-04-24

Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.

New York Blood Center Enterprises · Rockville Centre, New York · Biologics · 2026-01-12

Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.

New York Blood Center Enterprises · Massapequa, New York · Biologics · 2025-12-12

Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.

Biomat USA Inc · Zanesville, Ohio · Biologics · 2025-12-09

Failure to use supplies and reagents in a manner consistent with instructions provided by the manufacturer.

New York Blood Center Enterprises · Melville, New York · Biologics · 2025-12-05

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →